Pharmacyte biotech inc (otcmkts pmcb) bouncing after another solid study – oracle dispatch type 1 diabetes ppt

Pharmacyte Biotech Inc (OTCMKTS:PMCB) just announced a successful run for its cancer and diabetes tech, Cell-in-a-Box. The three year study has created a large bank of knowledge on genetically modified cells in preparation for a submission to the FDA. In short, the pancreatic cells showed positive signs and the study results keep the company on track to test a product.

Kenneth L Waggoner, Chief Executive Officer of PharmaCyte, said, “We are delighted with the results of these long-term studies. They are crucial to demonstrating the long-term functionality and other characteristics of our genetically engineered cells, the ‘Active Pharmaceutical Ingredient (API),’ we plan to encapsulate as part of our therapy for LAPC. We have shown the API continues to function as designed over lengthy periods of time.


We now have a large dossier of data to reference in our IND that documents each of the important characteristics of our API.”

Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes.

According to company materials, “PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.”

This news has seen investors come back to the stable with trading volume reaching above 4M on Monday. PMCB is one of the few OTC biotechs that is really worth watching and learning about as they progress toward a date with the FDA. The Cell in a Box Tech or their live-cell encapsulation technology is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed. This technology has multiple applications and PMCB is working toward pushing these products down the pipeline.

Sporting a current market cap value of $57.76M with a float of 976.06M, PMCB technology that continues to garner attention and potential investors need to be watching closely as more news is on the horizon. We will be providing more updates as they come. For continuing coverage on shares of $PMCB stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!